EcoDrugPlus

5-Hydroxytryptamine Receptor 1f

Ensembl ID : ENSOSIG00000007357
Gene Symbol: HTR1F
1 Cross references
140 Possible Orthologues:

5-Hydroxytryptamine Receptor 2a

Ensembl ID : ENSOSIG00000000111
Gene Symbol: HTR2A
1 Cross references
216 Possible Orthologues:

5-Hydroxytryptamine Receptor 3a

Ensembl ID : ENSOSIG00000021015
Gene Symbol: HTR3A
1 Cross references
203 Possible Orthologues:

5-Hydroxytryptamine Receptor 4

Ensembl ID : ENSOSIG00000020263
Gene Symbol: HTR4
1 Cross references
198 Possible Orthologues:

5-Hydroxytryptamine Receptor 6

Ensembl ID : ENSOSIG00000017589
Gene Symbol: HTR6
1 Cross references
114 Possible Orthologues:

5-Hydroxytryptamine Receptor 7

Ensembl ID : ENSOSIG00000017309
Gene Symbol: HTR7
1 Cross references
196 Possible Orthologues:

A-Raf Proto-Oncogene, Serine/threonine Kinase

Ensembl ID : ENSOSIG00000020017
Gene Symbol: ARAF
1 Cross references
191 Possible Orthologues:

Abl Proto-Oncogene 1, Non-Receptor Tyrosine Kinase

Ensembl ID : ENSOSIG00000000316
Gene Symbol: ABL1
1 Cross references
202 Possible Orthologues:

Adam Metallopeptidase Domain 17

Ensembl ID : ENSOSIG00000001260
Gene Symbol: ADAM17
1 Cross references
210 Possible Orthologues:

Adam Metallopeptidase Domain 17a

Ensembl ID : ENSOSIG00000016439
Gene Symbol: ADAM17A
1 Cross references
208 Possible Orthologues:

Adam Metallopeptidase With Thrombospondin Type 1 Motif 5

Ensembl ID : ENSOSIG00000017888
Gene Symbol: ADAMTS5
1 Cross references
199 Possible Orthologues:

Adrm1 26s Proteasome Ubiquitin Receptor

Ensembl ID : ENSOSIG00000016650
Gene Symbol: ADRM1
1 Cross references
194 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).